Figure 2.

(A–D) The symptoms of the patients’ nausea, appetite loss, dietary intake and vomiting following 193 cycles of triple combination therapy were significantly worse than following 226 cycles of double combination therapy on Day 1 (0.08±0.24 vs. 0.24±0.63, p=0.002; 0.24±0.61 vs. 0.46±0.84, p=0.002; 13.69±5.62 vs. 12.11±5.86, p=0.005; 0.02±0.19 vs. 0.09±0.39, p=0.02, respectively). However, there were no differences between the symptoms and treatment regimens on Day 5 (0.55±0.81 vs. 0.60±0.91, 1.10±0.89 vs. 1.14±0.97, 9.64±5.90 vs. 9.97±5.37, 0.00±0.00 vs. 0.00±0.00, respectively). Three symptoms (except for vomiting) were worse in the delayed phase (Day 5) compared with the acute phase (Day 1) regardless of aprepitant administration.